Effectiveness of UroLogic™ in reducing the symptoms of overactive bladder and urinary incontinence

Effectiveness of UroLogic™, a nutritional supplement containing Equisetum arvense and Crateva nurvala, in reducing the symptoms of overactive bladder (OAB) and urinary incontinence (UI) was evaluated in a randomized, double‐blind, placebo‐controlled trial. Individuals (men and women, age range 29–88 years) received either 1.58 grams/twice daily of UroLogic™ (n=46) or a placebo (n=27) daily for two months. The participants completed the validated Incontinence Impact Questionnaire (IIQ) and Urogenital Distress Inventory (UDI) at the beginning of the study (baseline), and again after one and two months of treatment. Mean scores were computed separately over all IIQ items dealing with interference of OAB and UI with daily activities and all UDI items dealing with distress caused by OAB and UI. Results revealed a significant improvement in symptoms after one month compared to baseline by subjects in both the UroLogic™ and placebo groups. Between month one and two; however, subjects treated with UroLogic™ generally maintained this improvement, whereas those on placebo generally returned to baseline level. Treatment with UroLogic™ for two months reduced the frequency and or leakage of urination in 85% of participants. In conclusion, the results of the study supported the effectiveness of UroLogic™ in reducing symptoms of OAB and UI.